Thu, Dec 06, 2012 01:33 - Diamyd Medical AB (DMYDY: OTC Link) released their Annual Report concerning Annual Report 11/12. To read the complete report, please visit: https://www.otciq.com/otciq/ajax/showFinancialReportById.pdf?id=96178.
Diamyd Medical AB (DMYDY: OTC Link) | Annual Report
↧
↧
Mako Hydrocarbons Ltd. (MAEEY: OTC Link) | Supplemental Information
Thu, Dec 06, 2012 01:53 - Mako Hydrocarbons Ltd. (MAEEY: OTC Link) released their Supplemental Information concerning Trading Halt. To read the complete report, please visit: https://www.otciq.com/otciq/ajax/showFinancialReportById.pdf?id=96179.
↧
Mako Hydrocarbons Ltd. (MAEEY: OTC Link) | Supplemental Information
Thu, Dec 06, 2012 01:54 - Mako Hydrocarbons Ltd. (MAEEY: OTC Link) released their Supplemental Information concerning Suspension from Official Quotation. To read the complete report, please visit: https://www.otciq.com/otciq/ajax/showFinancialReportById.pdf?id=96180.
↧
Mako Hydrocarbons Ltd. (MAEEY: OTC Link) | Supplemental Information
Thu, Dec 06, 2012 01:56 - Mako Hydrocarbons Ltd. (MAEEY: OTC Link) released their Supplemental Information concerning Reinstatement to Offical Quotation. To read the complete report, please visit: https://www.otciq.com/otciq/ajax/showFinancialReportById.pdf?id=96181.
↧
Mako Hydrocarbons Ltd. (MAEEY: OTC Link) | Management Discussion and Analysis
Thu, Dec 06, 2012 02:26 - Mako Hydrocarbons Ltd. (MAEEY: OTC Link) released their Management Discussion and Analysis concerning Letter to Shareholders and Management's Discussion & Analysis for the three & nine months ended September 30, 2012. To read the complete report, please visit: https://www.otciq.com/otciq/ajax/showFinancialReportById.pdf?id=96182.
↧
↧
Mako Hydrocarbons Ltd. (MAEEY: OTC Link) | Interim Financial Report
Thu, Dec 06, 2012 02:28 - Mako Hydrocarbons Ltd. (MAEEY: OTC Link) released their Interim Financial Report concerning Unaudited Financial Statements for the three & nine months ended September 30, 2012. To read the complete report, please visit: https://www.otciq.com/otciq/ajax/showFinancialReportById.pdf?id=96183.
↧
Strategic Environmental & Energy Resources, Inc. (SENR: OTC Link) | Annual Report
Thu, Dec 06, 2012 02:48 - Strategic Environmental & Energy Resources, Inc. (SENR: OTC Link) released their Annual Report concerning SEER 2010 Audited Financials. To read the complete report, please visit: https://www.otciq.com/otciq/ajax/showFinancialReportById.pdf?id=96184.
↧
Everton Resources Inc. (EVRRF: OTC Link) | EVR Notice of change of auditor
↧
Imperial Tobacco Group PLC (ITYBY: OTC Link) | Transaction in Own Shares
Imperial Tobacco Group PLC - Transaction in Own Shares
Purchase of own securities
The purchased shares will all be held as treasury shares. Following the above purchase, Imperial Tobacco holds 81,623,132 ordinary shares as treasury shares. The total number of ordinary shares in issue (excluding shares held as treasury shares) is 986,319,749.
Contacts:
John Nelson-Smith | Imperial Tobacco Group PLC | 0117 933 7032 |
Copies of our announcements are available on our website: www.imperial-tobacco.com
↧
↧
Fission Energy Corp. (FSSIF: OTC Link) | FISSION INCREASES 43-101 RESOURCE AT J ZONE ON ITS WATERBURY LAKE PROJECT
↧
Aldila, Inc. (ALDA: OTC Link) | Aldila Shareholder Meeting Proxy Statement
↧
Diamyd Medical AB (DMYDY: OTC Link) | Bulletin from Annual General Meeting of Diamyd Medical AB
The following items were addressed at the Annual General Meeting of Diamyd Medical AB (publ) held today:
Diamyd Medical's President and CEO Peter Zerhouni gave a retrospective view of the past year and summarized the most significant events that took place during the fiscal year and after year-end.
The Company's income statements and balance sheets were adopted and the Board members and the Chief Executive Officer were discharged from liability for the 2011/2012 fiscal year. The Annual General Meeting approved the Board's proposal that no dividend be paid for the 2011/2012 fiscal year.
Anders Essen-Möller was re-elected as Chairman of the Board and Maria-Teresa Essen-Möller was re-elected to the Board. Erik Nerpin and Jonas Jendi were elected as new Board members. Erik Nerpin, born in 1961, is an attorney and partner at Kilpatrick Townsend in Stockholm. Jonas Jendi, born in 1970, M.Sc. Economics & Business Administration, has spent the last 10 years managing the company Cogmed. Cogmed is based on research from the Karolinska Institute and was acquired by Pearson in 2010. The former Board members Lars Jonsson, Joseph Janes and Christer Lindberg have declined re-election.
The Annual General Meeting approved the proposed guidelines for remuneration of the CEO and other senior executives. The Meeting also approved the proposed remuneration to Board members and the Chairman of the Board.
The Annual General Meeting resolved to re-elect the auditing company Öhrlings PricewaterhouseCoopers until the end of the Annual General Meeting 2013. Principal auditor is the authorized public accountant Eva Blom.
The Annual General Meeting approved the proposed principles for the appointment of Nomination Committee for the 2013 Annual General Meeting.
The Annual General Meeting resolved to authorize the Board to approve new share issues for a maximum total of 10 percent of the number of shares on one or more occasions before the next Annual General Meeting, and permit the Board to deviate from the shareholders’ preferential rights when so doing. Payment may be made in cash, through a contribution or by offsetting.
The Annual General Meeting resolved to authorize the Board, for the period until the next Annual General Meeting, to repurchase series B shares in Diamyd Medical on Nasdaq OMX Stockholm. The maximum number of shares repurchased shall be such that Diamyd Medical shares held in treasury from time to time do not exceed ten percent of all shares in Diamyd Medical.
For more information, please contact:
Peter Zerhouni, President and CEO Diamyd Medical AB
Phone: +46 8 661 00 26. E-mail: press@diamyd.com
About Diamyd Medical
Diamyd Medical was founded in 1996 and is active in the field of pharmaceutical development. Diamyd Medical is headquartered in Stockholm, Sweden. The Company’s development project consists of the protein GAD65 for the treatment and prevention of autoimmune diabetes. A Swedish researcher-initiated Phase II study is ongoing to evaluate whether GAD65 can prevent type 1 diabetes in children who are at high risk of developing the disease.
Diamyd Medical also has holdings in the gene therapy company Periphagen Holdings, Inc. (USA), the vaccine company Protein Sciences Corporation (USA) and the diagnostics company Mercodia AB (Sweden).
Diamyd shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL). Further information is available on the Company’s website: www.diamyd.com.
This information is disclosed in accordance with the Swedish Securities Markets Act, the Swedish Financial Instruments Trading Act, or the requirements stated in the listing agreements.
Diamyd Medical AB (publ)
Karlavägen 108, SE-115 26 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com. Reg. no: 556530-1420
Diamyd Medical's President and CEO Peter Zerhouni gave a retrospective view of the past year and summarized the most significant events that took place during the fiscal year and after year-end.
The Company's income statements and balance sheets were adopted and the Board members and the Chief Executive Officer were discharged from liability for the 2011/2012 fiscal year. The Annual General Meeting approved the Board's proposal that no dividend be paid for the 2011/2012 fiscal year.
Anders Essen-Möller was re-elected as Chairman of the Board and Maria-Teresa Essen-Möller was re-elected to the Board. Erik Nerpin and Jonas Jendi were elected as new Board members. Erik Nerpin, born in 1961, is an attorney and partner at Kilpatrick Townsend in Stockholm. Jonas Jendi, born in 1970, M.Sc. Economics & Business Administration, has spent the last 10 years managing the company Cogmed. Cogmed is based on research from the Karolinska Institute and was acquired by Pearson in 2010. The former Board members Lars Jonsson, Joseph Janes and Christer Lindberg have declined re-election.
The Annual General Meeting approved the proposed guidelines for remuneration of the CEO and other senior executives. The Meeting also approved the proposed remuneration to Board members and the Chairman of the Board.
The Annual General Meeting resolved to re-elect the auditing company Öhrlings PricewaterhouseCoopers until the end of the Annual General Meeting 2013. Principal auditor is the authorized public accountant Eva Blom.
The Annual General Meeting approved the proposed principles for the appointment of Nomination Committee for the 2013 Annual General Meeting.
The Annual General Meeting resolved to authorize the Board to approve new share issues for a maximum total of 10 percent of the number of shares on one or more occasions before the next Annual General Meeting, and permit the Board to deviate from the shareholders’ preferential rights when so doing. Payment may be made in cash, through a contribution or by offsetting.
The Annual General Meeting resolved to authorize the Board, for the period until the next Annual General Meeting, to repurchase series B shares in Diamyd Medical on Nasdaq OMX Stockholm. The maximum number of shares repurchased shall be such that Diamyd Medical shares held in treasury from time to time do not exceed ten percent of all shares in Diamyd Medical.
For more information, please contact:
Peter Zerhouni, President and CEO Diamyd Medical AB
Phone: +46 8 661 00 26. E-mail: press@diamyd.com
About Diamyd Medical
Diamyd Medical was founded in 1996 and is active in the field of pharmaceutical development. Diamyd Medical is headquartered in Stockholm, Sweden. The Company’s development project consists of the protein GAD65 for the treatment and prevention of autoimmune diabetes. A Swedish researcher-initiated Phase II study is ongoing to evaluate whether GAD65 can prevent type 1 diabetes in children who are at high risk of developing the disease.
Diamyd Medical also has holdings in the gene therapy company Periphagen Holdings, Inc. (USA), the vaccine company Protein Sciences Corporation (USA) and the diagnostics company Mercodia AB (Sweden).
Diamyd shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL). Further information is available on the Company’s website: www.diamyd.com.
This information is disclosed in accordance with the Swedish Securities Markets Act, the Swedish Financial Instruments Trading Act, or the requirements stated in the listing agreements.
Diamyd Medical AB (publ)
Karlavägen 108, SE-115 26 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com. Reg. no: 556530-1420
↧
Great Western Minerals Group Ltd. (GWMGF: OTC Link) | GREAT WESTERN MINERALS GROUP RECEIVES TSXV APPROVAL FOR WARRANT EXTENSION
GREAT WESTERN MINERALS GROUP LTD.
TSX Venture Symbol: GWG CUSIP: 39141Y 10 3
OTCQX: GWMGF
GREAT WESTERN MINERALS GROUP RECEIVES TSXV APPROVAL FOR WARRANT EXTENSION
December 6, 2012 - Saskatoon, Canada: Great Western Minerals Group Ltd. ("GWMG" or the "Company", TSX:V – GWG) announces that it has received approval from the TSX Venture Exchange (the "TSXV") for an extension of the expiry date of certain of GWMG's outstanding common share purchase warrants (the "Warrants").
GWMG has received TSXV approval for the extension of the expiry date from December 15, 2012 to January 15, 2013 for 41,413,723 Warrants originally issued on October 19, 2010 and having an exercise price of $0.45 per Warrant (see GWMG news release December 6, 2012). The exercise price of the Warrants remains unchanged.
Warrant holders will not be issued replacement Warrant certificates and the Warrant holders will be required to present the original Warrant certificates in order to effect the exercise of such Warrants.
Great Western Minerals Group Ltd. is engaged in becoming an integrated rare earth producer. The Company currently produces specialty alloys which are used in the aerospace, automobile, computer and high-tech industries. Produced at the Company’s wholly owned subsidiaries Less Common Metals Limited in Birkenhead, U.K. and Great Western Technologies Inc. in Troy, Michigan, these alloys contain iron, nickel, cobalt and rare earth elements. As part of the Company’s vertical integration strategy, GWMG also holds 100% equity ownership in Rare Earth Extraction Co. Limited, which owns a 74% equity interest in the Steenkampskraal Mine in South Africa. In addition to an exploration program at Steenkampskraal, GWMG also holds interests in four active rare earth exploration and development properties in North America.
For further information, please contact Dwight Percy, Manager of Investor Relations at (306) 659-4516. Email inquiries should be made to info@gwmg.ca and the company website is located at www.gwmg.ca. Inquiries by direct mail should be addressed to Great Western Minerals Group Ltd., 219 Robin Crescent, Saskatoon, SK S7L 6M8.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
↧
↧
Armanino Foods of Distinction, Inc. (AMNF: OTC Link) | ARMANINO FOODS OF DISTINCTION, INC., ANNOUNCES REGULAR QUARTERLY DIVIDEND
↧
Strategic Environmental & Energy Resources, Inc. (SENR: OTC Link) | SEER Financing Final
↧
Papuan Precious Metals Corp (PAUFF: OTC Link) | PPM Annual General Meeting Highlights
PAPUAN PRECIOUS METALS CORP. (“PPM” or the “Company”) held its 2012 Annual General Meeting (“
↧
Papuan Precious Metals Corp (PAUFF: OTC Link) | PPM Sells interest in Mount Suckling Project
PAPUAN PRECIOUS METALS CORP (“PPM or the “Company”) has entered into an agreement to sell a 90% interest in its
The completion of the transaction is subject to a number of conditions, including but not limited to TSX Venture Exchange approval.
About Papuan Precious Metals Corp.
PPM is engaged in the acquisition, exploration and development of mineral properties with a focus on Copper-Gold porphyries in
ON BEHALF OF THE BOARD
“Dev Randhawa”
Dev Randhawa, Chairman and CEO
For further information contact:
Greg Downey at 1.866.979.7022
Or email: info@ppmpng.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
↧
↧
USA Graphite Inc. (USGT: OTC Link/FINRA BB) | Caveat Emptor Status Change
Thu, Dec 06, 2012 12:00 - USA Graphite Inc. (USGT: OTC Link/FINRA BB) - Caveat Emptor Status Change - The symbol, USGT, has been added to the Caveat Emptor classification. You may find a complete list of Caveat Emptor status changes at otcmarkets.com.
↧
MIT Holding, Inc. (MITD: OTC Link) | Tier Change
Fri, Dec 07, 2012 12:00 - MIT Holding, Inc. (MITD: OTC Link) - Tier Change - The symbol, MITD, no longer is classified as OTC Pink Limited. As of Fri, Dec 07, 2012, MITD resides in the OTCQB tier. You may find a complete list of tier changes at otcmarkets.com.
↧
Quantitative Alpha Trading, Inc. (QATSF: OTC Link) | Tier Change
Fri, Dec 07, 2012 12:00 - Quantitative Alpha Trading, Inc. (QATSF: OTC Link) - Tier Change - The symbol, QATSF, no longer is classified as OTCQB. As of Fri, Dec 07, 2012, QATSF resides in the OTC Pink Limited tier. You may find a complete list of tier changes at otcmarkets.com.
↧
More Pages to Explore .....
